Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)

Ashley L. Eadie; Keith R. Brunt; Matthew Herder

doi:10.1002/prp2.794

Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)

Ashley L. Eadie, Keith R. Brunt, Matthew Herder

Psychology

科研成果: 期刊稿件 › 文献综述 › 同行评审

14 引用（Scopus）

源语言	英语
文章编号	e00794
期刊	Pharmacology Research and Perspectives
卷	9
期	3
DOI	https://doi.org/10.1002/prp2.794
出版状态	已出版 - 6月 2021

!!!ASJC Scopus Subject Areas

神经病学
药理学、毒理学和药学（全部）

访问文件

10.1002/prp2.794

其它文件与链接

引用此

Eadie, A. L., Brunt, K. R., & Herder, M. (2021). Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan). Pharmacology Research and Perspectives, 9(3), 文章 e00794. https://doi.org/10.1002/prp2.794

@article{c777ba1a84a34ae3a742f94782d63663,

title = "Exploring the Food and Drug Administration{\textquoteright}s review and approval of Entresto (sacubitril/valsartan)",

keywords = "NT-proBNP, PARADIGM-HF, PARAGON-HF, pediatric heart failure, postmarketing requirements, sex differences",

author = "Eadie, {Ashley L.} and Brunt, {Keith R.} and Matthew Herder",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.",

year = "2021",

month = jun,

doi = "10.1002/prp2.794",

language = "English",

volume = "9",

journal = "Pharmacology Research and Perspectives",

issn = "2052-1707",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)

AU - Eadie, Ashley L.

AU - Brunt, Keith R.

AU - Herder, Matthew

N1 - Publisher Copyright: © 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

PY - 2021/6

Y1 - 2021/6

KW - NT-proBNP

KW - PARADIGM-HF

KW - PARAGON-HF

KW - pediatric heart failure

KW - postmarketing requirements

KW - sex differences

UR - http://www.scopus.com/inward/record.url?scp=85107459096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107459096&partnerID=8YFLogxK

U2 - 10.1002/prp2.794

DO - 10.1002/prp2.794

M3 - Review article

C2 - 34087050

AN - SCOPUS:85107459096

SN - 2052-1707

VL - 9

JO - Pharmacology Research and Perspectives

JF - Pharmacology Research and Perspectives

IS - 3

M1 - e00794

ER -

Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)

!!!ASJC Scopus Subject Areas

访问文件

其它文件与链接

指纹

引用此